Literature DB >> 25858357

Validation of the Japanese version of the Chronic Liver Disease Questionnaire for the assessment of health-related quality of life in patients with chronic viral hepatitis.

Atsushi Tanaka1, Kentaro Kikuchi2, Ryo Miura1, Kotaro Miura1, Masaki Mikami1, Mitsuhiko Aiso1, Yoriyuki Takamori1, Hajime Takikawa1.   

Abstract

AIM: Patients with chronic liver diseases (CLD) suffer from a variety of subjective symptoms, and the assessment of health-related quality of life (HRQOL) is crucial. The Chronic Liver Disease Questionnaire (CLDQ) is the first liver disease-specific instrument for this purpose. In this study we aimed to develop the Japanese version of CLDQ and to assess its validity and reliability in Japanese patients with chronic viral hepatitis.
METHODS: The participants included 135 Japanese patients chronically infected with hepatitis B or C virus. The Japanese version of the CLDQ was developed according to the standard "back-translation" method. In addition to the Japanese version of the CLDQ, we asked the patients to fill out two other self-report questionnaires: the Japanese versions of the 36-Item Short Form Survey (SF-36) and Hospital Anxiety and Depression Scale (HADS). Then, the internal consistency, convergent and discriminant validity of the Japanese version of CLDQ were statistically examined.
RESULTS: Cronbach's alpha of the Japanese version of the CLDQ was acceptable. The mean score was lower in emotional domains of the CLDQ, compared with those in somatic domains. Pearson correlations between Japanese CLDQ and SF-36 and HADS were significant. The mean of the CLDQ scores decreased in all domains in patients with liver cirrhosis compared with those in patients with chronic hepatitis.
CONCLUSION: The Japanese version of the CLDQ is a reliable and valid instrument for assessment of the HRQOL of Japanese patients with chronic viral hepatitis. The results also suggest that the HRQOL of Japanese patients is mainly impaired by emotional factors rather than somatic symptoms, and significantly worsened by progression of the disease.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  36-Item Short Form Survey; Hospital Anxiety and Depression Scale; chronic liver disease; health-related quality of life

Year:  2015        PMID: 25858357     DOI: 10.1111/hepr.12524

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  11 in total

1.  Translation and validation of chronic liver disease questionnaire (CLDQ) in Tamil language.

Authors:  Amit Goel; Karunanithi Arivazhagan; Avani Sasi; Vanathy Shanmugam; Seleena Koshi; Biju Pottakkat; C P Lakshmi; Ashish Awasthi
Journal:  Indian J Gastroenterol       Date:  2017-06-13

2.  Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy.

Authors:  Yuka Aimono; Noriko Kohyama; Toshiro Kamoshida; Toshinori Yamamoto; Mari Kogo
Journal:  Eur J Hosp Pharm       Date:  2020-04-03

3.  LC-PROM: Validation of a patient reported outcomes measure for liver cirrhosis patients.

Authors:  Ying Zhang; Yuanyuan Yang; Jing Lv; Yanbo Zhang
Journal:  Health Qual Life Outcomes       Date:  2016-05-10       Impact factor: 3.186

4.  Translation, adaptation and validation of two versions of the Chronic Liver Disease Questionnaire in Malaysian patients for speakers of both English and Malay languages: a cross-sectional study.

Authors:  Shasha Khairullah; Sanjiv Mahadeva
Journal:  BMJ Open       Date:  2017-05-25       Impact factor: 2.692

5.  Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus.

Authors:  Hiroki Ikeda; Tsunamasa Watanabe; Nobuyuki Matsumoto; Tetsuya Hiraishi; Hiroyasu Nakano; Yohei Noguchi; Nobuhiro Hattori; Ryuta Shigefuku; Masaki Yamashita; Kazunari Nakahara; Kotaro Matsunaga; Chiaki Okuse; Hiroshi Yotsuyanagi; Atsushi Tanaka; Michihiro Suzuki; Fumio Itoh
Journal:  JGH Open       Date:  2018-05-14

6.  Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.

Authors:  Atsushi Takahashi; Kei Moriya; Hiromasa Ohira; Teruko Arinaga-Hino; Mikio Zeniya; Takuji Torimura; Masanori Abe; Akinobu Takaki; Jong-Hon Kang; Ayano Inui; Tomoo Fujisawa; Kaname Yoshizawa; Yoshiyuki Suzuki; Nobuhiro Nakamoto; Kazuhiko Koike; Hitoshi Yoshiji; Aya Goto; Atsushi Tanaka; Zobair M Younossi; Hajime Takikawa
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

7.  Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis.

Authors:  Akira Sakamaki; Masaaki Takamura; Norihiro Sakai; Yusuke Watanabe; Yoshihisa Arao; Naruhiro Kimura; Toru Setsu; Hiroyuki Abe; Takeshi Yokoo; Hiroteru Kamimura; Shunsuke Tsubata; Nobuo Waguri; Toru Ishikawa; Hirokazu Kawai; Soichi Sugitani; Tomomi Sato; Kazuhiro Funakoshi; Masashi Watanabe; Kentarou Igarashi; Kenya Kamimura; Atsunori Tsuchiya; Yutaka Aoyagi; Shuji Terai
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

8.  Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.

Authors:  Akio Miyasaka; Yuichi Yoshida; Akiko Suzuki; Yasuhiro Takikawa
Journal:  Qual Life Res       Date:  2021-05-19       Impact factor: 4.147

9.  Quality of life among patients with autoimmune hepatitis in remission: A comparative study.

Authors:  Atsushi Takahashi; Masanori Abe; Tetsuya Yasunaka; Teruko Arinaga-Hino; Kazumichi Abe; Akinobu Takaki; Takuji Torimura; Mikio Zeniya; Kaname Yoshizawea; Jong-Hon Kang; Yoshiyuki Suzuki; Nobuhiro Nakamoto; Ayano Inui; Atsushi Tanaka; Hajime Takikawa; Hiromasa Ohira
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

10.  Assessment of health-related quality of life and related factors in patients with chronic liver disease.

Authors:  Neila Paula de Souza; Livia Melo Villar; Artênio José Ísper Garbin; Tânia Adas Saliba Rovida; Cléa Adas Saliba Garbin
Journal:  Braz J Infect Dis       Date:  2015-09-09       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.